Joined in 2023 
82 
63 About this deal
All identified babies must be notified by providers to NCARDRS as are other structural and chromosomal anomalies. Data items on dates and cardiac findings of fetal anomaly scans, repeat scans, expected date of delivery, date of booking to be completed/validated by relevant service of booking/screening. National performance of ST4a (see standard SCT-S05) in Q2 was 50.6%, higher than the previous quarter. The trend graph below shows England ST4a performance since the KPI was first published in Q1 2019 to 2020. Thresholds have not yet been set for this KPI. present to the service at or after 23 weeks plus 1 day (as they are not part of the eligible population for the screening programme) National performance of NB2 (see standard NBS-S06) in Q4 was 2.1%, lower than the previous quarter. The trend graph below shows that England NB2 performance is above the acceptable threshold of 2%. NB2 is a KPI where a lower performance is better.
The eligibility criteria for entry into the combined screening pathway is a baby’s CRL measurement between 45.0mm and 84.0mm. This is equal to 11 weeks plus 2 days to 14 weeks plus 1 day of pregnancy. out of 139 screening services submitted data, including 51 services that reported zero women at risk. return data for the test standard FASP-S05: turnaround time and test standard FASP-S06: inadequate samples ( KPI FA4)Numerator: number of samples received in the laboratory that were inadequate due to at least one of the following criteria: make sure women with a higher chance result following combined or quadruple screening are offered an appointment in ≤ 3 working days of the result being available to discuss the options of: The proportion of women with higher chance T21, T18, T13 screening results attending an appointment in ≤ 3 working days to discuss their results. Rationale Denominator: number of samples received for karyotype testing where the indication for genetic testing is a higher chance T21, T18, T13 screening result issued in the reporting period Thresholds are not set for this standard. FASP supports personal informed choice for women. There is no intention to publish performance of this data by maternity service. This standard supports the safety of the screening pathway by enabling screening services to be assured that:
offer screening to assess the chance of the baby being born with Down’s syndrome, Edwards’ syndrome or Patau’s syndrome - some women may choose not to be screened, or accept screening for some conditions and not others, and it is important their choice is respected This standard monitors the true detection of the screening tests. This standard provides assurance that the screening tests are performing at optimal levels. Definition Down’s syndrome (T21) combined testFASP defines the national cut-off set at 1 in 150 at term for both first and second trimester screening tests. A woman with a result of 1 in 150 or greater (between 1 in 2 and 1 in 150), of having a pregnancy with T21, T18, T13 in the first trimester, or T21 only in the second trimester, is considered to be in the ‘higher chance’ group and offered an invasive diagnostic test. Denominator: number of women who had a screening scan within the reporting period with an unexpected finding and were referred to a tertiary centre. These revised screening standards for the NHS fetal anomaly screening programme ( FASP) replace previous versions. They apply to data collected from 1 April 2022 unless stated otherwise in the document.
Great Deal 
New Comment